Guorong Fan | Pharmaceutical Analysis | Best Researcher Award
Prof. Guorong Fan, Shanghai Jiao Tong University, China.
Publivation Profiles
SCOPUS
Education and Experience
Education:
- Ph.D. in Pharmaceutical Sciences
- M.Sc. in Pharmacy
- B.Sc. in Pharmacy
Professional Experience:
- Professor, School of Pharmacy, Shanghai Jiao Tong University
- Led 50+ major research projects in drug metabolism & kinetics
- Published 140+ SCI papers in top journals
- Editorial board member of leading pharmaceutical journals
- Conducted collaborative research with UCLA & Free University of Brussels
Suitability summary
Professor Guorong Fan, a distinguished researcher at the School of Pharmacy, Shanghai Jiao Tong University, is a highly suitable candidate for the Best Researcher Award due to his groundbreaking contributions to pharmaceutical analysis, pharmacokinetics, and clinical pharmacy. With a prolific academic career spanning over 140 SCI publications, he has significantly advanced the fields of drug metabolism, bioavailability evaluation, and innovative analytical techniques. His work has shaped global pharmaceutical research and development, making him a leading figure in the industry.
Professional Development
Guorong Fan has played a crucial role in advancing pharmaceutical sciences through international collaborations, drug formulation studies, and pharmacokinetics research. His expertise in HPLC, LC-MS, and clinical drug monitoring has led to high-impact innovations in the field. As an editorial board member, he ensures the quality and integrity of pharmaceutical research publications. Additionally, his work on preclinical drug metabolism and kinetic studies has contributed to several drug approvals. Through mentorship and industry partnerships, he continues to shape the future of pharmaceutical analysis and drug development globally.
Research Focus
- Differences in hypersensitivity reactions and gadolinium deposition disease based on global databases
– BMC Medicine, 2024 – Cited by: 1
- Five years of safety profile of bevacizumab: pharmacovigilance and RCT analysis
– Journal of Pharmaceutical Health Care and Sciences, 2024 – Cited by: 5
- Advances in therapeutic drug monitoring of invasive fungal disease
– China Pharmacy, 2024
- Altered biliary microbial and metabolic profile in NAFLD and cholelithiasis
– Clinics and Research in Hepatology and Gastroenterology, 2024
- Cost-utility analysis and drug pricing for tirzepatide vs. semaglutide in China
– Diabetes, Obesity and Metabolism, 2024 – Cited by: 2
- Mining of anaphylaxis associated with oxaliplatin using FDA adverse event database
– Chinese Journal of Hospital Pharmacy, 2024